Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|September 26, 2024
MEF2A restrains cisplatin resistance in gastric cancer cells by modulating NFKBIA/NF-κB signaling pathwayChenghao Chu, Yongwei Zhang, Ruiran Yu, et al.
ACS Applied Materials & Interfaces|April 23, 2021
High-Yield Two-Dimensional Metal-Organic Framework Derivatives for Wideband Electromagnetic Wave AbsorptionGuang Liu, Jiaqi Tu, Chen Wu, et al.
American Journal of Physiology. Cell Physiology|June 28, 2018
Transgelin induces dysfunction of fetal endothelial colony-forming cells from gestational diabetic pregnanciesKaela M Varberg, Rashell O Garretson, Emily K Blue, et al.
Oncotarget|September 17, 2017
Folate metabolism genetic polymorphisms and meningioma and glioma susceptibility in adultsDongming Chen, Jun Dong, Ying Huang, et al.
American Journal of Physiology. Cell Physiology|January 20, 2017
Kinetic analyses of vasculogenesis inform mechanistic studiesKaela M Varberg, Seth Winfree, Chenghao Chu, et al.
Pain|October 1, 2019
A randomized controlled trial testing a virtual perspective-taking intervention to reduce race and socioeconomic status disparities in pain careAdam T Hirsh, Megan M Miller, Nicole A Hollingshead, et al.
American Journal of Respiratory and Critical Care Medicine|October 27, 2023
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related EventsBonnie Ramsey, Christoph U Correll, David R DeMaso, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Clinical TrialClaire Wainwright, Susanna A McColley, Paul McNally, et al.
American Journal of Respiratory and Critical Care Medicine|June 2, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension StudyClaire Wainwright, Susanna A McColley, Paul McNally, et al.
American Journal of Respiratory and Critical Care Medicine|March 15, 2023
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One <i>F508del</i> AlleleJennifer L Goralski, Jordana E Hoppe, Marcus A Mall, et al.
Pageof 3